STOCK TITAN

CareDx, Inc. - CDNA STOCK NEWS

Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.

CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.

CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.

The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.

CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.

Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced the American Society of Transplant Surgeons (ASTS) supports its AlloSure Kidney and AlloMap Heart testing for organ transplant surveillance. The ASTS position statement endorses the use of donor-derived cell-free DNA (dd-cfDNA) to monitor kidney transplant recipients, particularly to rule out subclinical antibody-mediated rejection (ABMR). It also recommends dd-cfDNA for heart transplants and peripheral blood gene expression profiling as a non-invasive diagnostic tool for heart transplant recipients over 55 days post-transplant. CEO Reg Seeto praised ASTS for this leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) announced it will not participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference due to scheduling conflicts. The Company is focused on providing high-value healthcare solutions for transplant patients and their caregivers. CareDx specializes in precision medicine, offering testing services and digital healthcare solutions throughout the transplant journey. The Company looks forward to releasing its next corporate update soon, indicating ongoing engagement with investors and stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA), known as The Transplant Company™, announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference. The presentation is scheduled for Monday, March 6, 2023, at 4:35 PM ET. Investors can access the webcast by visiting CareDx's investor relations page at investors.caredxinc.com. CareDx is a leader in precision medicine solutions, offering innovative testing services and digital healthcare solutions for transplant patients throughout their journey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.73%
Tags
conferences
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) announced the release of a Billing Article regarding MolDX Molecular Testing for Solid Organ Allograft Rejection, effective March 31, 2023. CEO Reg Seeto clarified that MolDX will not modify the foundational LCD but issued this article for clarification. Key points include reimbursement coverage for testing services, standalone billing for AlloSure Heart, which can now be billed separately from AlloMap Heart, and a pathway for multimodality testing with additional data. CareDx plans to engage further with MolDX and update their HeartCare submission and procedures accordingly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced its eighth consecutive sponsorship of the National Kidney Foundation's Annual Kidney Patient Summit, scheduled for March 1-2, 2023, on Capitol Hill. This event aims to raise awareness about kidney disease during National Kidney Month. CareDx aims to enhance patient care and promote early detection of chronic kidney disease. The company invests in transplant innovations, supporting various legislative policies, including the Living Donor Protection Act. CEO Reg Seeto emphasized their commitment to improving the patient journey from early interventions to post-transplant monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) reported its financial results for Q4 and the full year 2022. The company achieved full-year revenue of $321.8 million, a 9% increase from 2021, with Q4 revenue hitting $82.4 million, up 4% year-over-year. Testing volumes for AlloMap and AlloSure grew by 19% to approximately 182,000 tests for 2022. However, the net loss increased to $76.6 million for the year, from $30.7 million in 2021. Cash and equivalents stand at $293 million. For 2023, CareDx anticipates revenue between $328 million and $338 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.34%
Tags
none
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) announced its participation in the American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting in Scottsdale, Arizona, from February 23-25. The company will showcase advancements in molecular diagnostics and artificial intelligence aimed at improving the health of transplant patients. A symposium titled 'Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence' is scheduled for February 24, featuring a panel of leading experts in transplantation. CareDx emphasizes its commitment to innovation and enhancing long-term allograft health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced it will report its financial results for the fourth quarter and full year 2022 on February 27, 2023, after market closure. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for management to discuss the results. Interested parties can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), referencing Conference ID: 13736063. CareDx specializes in precision medicine solutions for transplant patients, delivering testing services and products throughout the patient journey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences earnings
-
Rhea-AI Summary

CareDx, a precision medicine company, is set to present its innovative solutions for cellular transplant and therapy at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. CEO Reg Seeto emphasized the importance of these advancements in cell therapy monitoring and digital health. Notable presentations include AutoCell™, a high-sensitivity solution for CAR-T cell monitoring, and various digital health solutions aimed at improving patient care across transplant centers. CareDx's offerings include workflow management, medication adherence solutions, and remote monitoring tools designed for effective patient engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary

CareDx, Inc. (CDNA) announced the publication of a guide in the Journal of the American College of Cardiology to assist clinicians in transitioning from invasive endomyocardial biopsies (EMB) to non-invasive monitoring for heart transplant rejection using AlloMap GEP and AlloSure dd-cfDNA. The guide highlights the clinical utility of these non-invasive tests, emphasizing their effectiveness in rejection surveillance. CareDx's HeartCare services are now utilized in over 90% of U.S. heart transplant centers, reflecting a growing trend towards non-invasive practices in heart transplant monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none

FAQ

What is the current stock price of CareDx (CDNA)?

The current stock price of CareDx (CDNA) is $23.13 as of November 22, 2024.

What is the market cap of CareDx (CDNA)?

The market cap of CareDx (CDNA) is approximately 1.2B.

What does CareDx, Inc. specialize in?

CareDx, Inc. specializes in precision medicine and surveillance management solutions aimed at improving the lives of organ transplant patients.

What is AlloSure®?

AlloSure® is a non-invasive blood test that measures allograft injury and detects donor-derived cell-free DNA (dd-cfDNA) to identify organ injury in kidney transplant patients.

Which organs do CareDx's products focus on?

CareDx's products focus on kidney, heart, and lung transplants.

Where does CareDx generate most of its revenue?

CareDx generates the majority of its revenue from the United States, primarily through its testing services.

What are some key products offered by CareDx?

Key products include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, all of which are dd-cfDNA solutions.

How does CareDx support transplant patients?

CareDx supports transplant patients by offering non-invasive diagnostic tests that help in monitoring and managing organ transplant health.

What technology does CareDx use in its diagnostics?

CareDx uses genomics and bioinformatics technology, specifically next-generation sequencing (NGS) to develop its diagnostic tests.

Does CareDx collaborate with other healthcare institutions?

Yes, CareDx partners with leading healthcare institutions to validate and implement their diagnostic solutions.

What kind of clinical evidence does CareDx generate?

CareDx generates high-quality clinical evidence through trials and registries to support the efficacy of its products.

What makes CareDx a leader in transplant diagnostics?

CareDx's combination of innovative diagnostic solutions, clinical evidence, and partnerships positions it as a leader in transplant diagnostics and surveillance.

CareDx, Inc.

Nasdaq:CDNA

CDNA Rankings

CDNA Stock Data

1.22B
51.79M
3.44%
96.1%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BRISBANE